The importance of IL-6 protein expression in primary human renal cell carcinoma: An immunohistochemical study

Journal of Clinical Pathology

Volumn 53, Issue 5, 2000, Pages 388-390

  Paule, Bernard ^a   Belot, Jacqueline ^a   Rudant, Christiane ^b   Coulombel, Colette ^b   Abbou, Claude Clément ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b CNRS   (France)

Author keywords

Immunohistochemistry; Interleukin 6; Renal cell carcinoma

Indexed keywords

INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER STAGING; CLINICAL ARTICLE; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-6; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 0034017924     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.53.5.388     Document Type: Article

References (15)

1. 1 Koo AS, Armstrong C, Bochner B, et al. Interleukin 6 and renal cancer production, regulation and growth effects. Cancer Immunol Immunother 1992;35:97-105.
2. 2 Blay JM, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992;52:3317-22.
3. 3 Tsukamaoto T, Kumamoto Y, Miyao N, et al. Interleukin-6 in renal cell carcinoma. J Urol 1992;148:1778-82.
4. 4 Blay JY, Bolon J, Alberte I, et al. Growth inhibition of renal carcinoma cell lines by interleukin 6 antisense oligonucleotides: an internal autocrine loop [abstract). Proceedings of the American Association of Clinical Research 1994;35:3557.
5. 5 Miki S, Iwano M, Miki Y. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinoma. FEBS Lett 1989;250:607-10.
6. 6 Takenawa J, Kanako Y, Fukijumoto M, et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 1991;83:1668-72.
7. 7 Weiss LM, Gelb AB, Medeiros LJ. Adult renal epithelial neoplasms. Am J Clin Pathol 1995;103:624-35.
8. 8 Storkel S, Eble J, Adlaka K, et al. Morphological classification of renal cell carcinoma. Cancer 1997;80:955 87.
9. 9 Furhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
10. 10 Paule R, Clere D, Rudant C, et al. Enhanced expression of interleukin-6 protein in bone and serum of metastatic renal cell carcinoma. Hum Pathol 1998;29:421-4.
11. 11 Costes V, Liautard J, Pico MC, et al. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J Clin Pathol 1997;50:835-40.
12. 12 Lu C, Vickers MF, Kerbel RS. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumour progression. Proc Natl Acad Sci U S A 1992;89:9215-19.
13. 13 Koo AS, Bochner B, de Kermion JB, et al. Production and regulation of interleukin-6 by renal cell carcinoma in vitro: protein activity and mRNA gene expression. Surg Forum 1990;41:710-13.
14. 14 Lagneaux L, Delforge A, Dorval C, et al. Excessive production of transforming growth factor β by bone marrow stroma cells in B cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin 6 production. Blood 1993;82:2379-85.
15. 15 Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992;50:1750-4.